ANZCHOG coordinates some of the most important childhood cancer research across Australia and New Zealand
Our clinical trials registry brings together every active and upcoming trial in one place – giving families, clinicians, and researchers a clear picture of what’s available, where, and for whom.
Whether you’re exploring options for a child in your care or looking for a study site, this registry is your starting point.
An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
>18 years
N/A
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients
1 year
|
31 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
>1 year
|
46 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
<21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital
A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed paediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
12 months
|
21 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
3 years
|
29 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk paediatric and Adult Patients with Germ Cell Tumors
Various depending on risk group & consult protocol
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group)
Application of innovative molecular profiling techniques to improve diagnosis of paediatric central nervous system tumours and develop an accredited Australasian molecular profiling service.
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
No limit
Royal Children’s Hospital, Women’s and Children’s Hospital, Children’s Hospital at Westmead
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL
>12 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital
A phase 1b study to evaluate the safety, tolerability, pharmacokinetics and efficacy of xaluritamig in adult, adolescent and paediatric participants with relapsed or refractory Ewing sarcoma
>2 years
Royal Children’s Hospital, Perth Children’s Hospital
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of
Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine
(DFMO) in Patients with Cancer
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
>1 year
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
189 days
|
22 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic Germ Cell Tumours
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
<40 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study
<25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
NCI-COG paediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
12 months
|
21 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
NCI-COG paediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
12 months
|
21 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
NCI-COG paediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
12 months
|
21 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
<50 years
Queensland Children’s Hospital, Children’s Hospital at Westmead
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
6 months
|
21 years
Perth Children’s Hospital, Children’s Hospital at Westmead
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in
childhood leukaemia
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban
A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma
≥ 1 year
John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital
A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in paediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
2 years
|
17 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Implementing pharmacogenetics in the busulfan dosing method for children undergoing hematopoietic stem-cell transplantation: a prospective, multicentric, randomized clinical trial
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
<30 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in paediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma
A Phase 1 Study of CD19 Specific Chimeric Antigen Receptor T-cell for Therapy of persistent and Relapsed B-cell leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study)
A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in paediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in paediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in paediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Cancer Information Registry for Children and Adolescents in Australia
No limit
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in paediatric patients with relapsed or refractory neuroblastoma and other solid tumors
12 months
|
21 years
N/A
CNS tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Soft tissue and bone tumours
A phase i/ii, open-label, single-arm, two-part trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in paediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma
Phase II Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent paediatric Adamantinomatous Craniopharyngioma
1 year
|
39 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital
A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
<18 years
Queensland Children’s Hospital, Monash Health Clayton, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Phase I/II Trial of Deflexifol for Refractory or Recurrent Paediatric CNS Tumours
12 months
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in paediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
6 months
|
25 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Women’s and Children’s Hospital, Children’s Hospital at Westmead
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma
A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR)
2 years
|
21 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated paediatric Patients <12 Years of Age With Severe Hemophilia A
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Westmead Adult Hospital
FaR-RMS (RG_17-247)
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
No limit
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Westmead Adult Hospital
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With paediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
<25 years
Sydney Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations
>10 years
Sydney Children’s Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
<10 years
Children’s Hospital at Westmead, Christchurch Hospital
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in paediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in paediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
<21 years
Perth Children’s Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in
Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and
Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
<20 years
Queensland Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in paediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
<17 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A clinical trial of donor-derived WT1 specific T cells for prevention of relapse in combination with multiple pathogen specific T cells for prevention of infection in patients undergoing allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Royal Adelaide Hospital
INTER-EWING-1 (RG_21-151)
International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 (INTER-EWING-1)
> 2 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital
International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
1 day
|
1 year
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
CAMPFIRE: A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in paediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in paediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the
Safety and Efficacy of Zilovertamab Vedotin in paediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
6 months
|
25 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital
Haematolymphoid disorders, Peripheral neuroblastic tumours, Soft tissue and bone tumours
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruta in paediatric Participants With Relapsed or Refractory Solid Tumors
1 months
|
17 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A
No limits
Queensland Children’s Hospital
Haematolymphoid disorders, Peripheral neuroblastic tumours, Soft tissue and bone tumours
Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain tumour.
7 years
|
21 years
John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Sir Charles Gardiner Hospital
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma
6 months
|
17 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
2 years
|
21 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in paediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
NANT 2012-01 Phase 1 study of Difluoromethylornithine (DFMO) and celecoxib with cyclophosphamide/topotecan for patients with relapsed or refractory neuroblastoma
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)
< 18 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
A Phase II Study of Panobinostat in Paediatric& Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma& Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
< 40 years
N/A
CNS tumours, Peripheral neuroblastic tumours, Soft tissue and bone tumours
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
No limit
Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours
1 year
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours
1 year
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant.
Multicentre, investigator-initiated phase I/II clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study
6 months
|
25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A Pharmacokinetic Study of Vincristine in Infants Dosed According to BSA Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
<12 years
N/A
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
6 months
|
25 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
2 years
|
39 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
1 year
|
39 years
John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in paediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation
A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Royal Adelaide Hospital - Sir Charles Gardiner Hospital
rEECur (RG_13-277)
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
≥ 2 years (no upper limit)
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital, Sir Charles Gardiner Hospital
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing Sarcoma
A Phase II Canadian paediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors
A retrospective cohort study of response and survival in paediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy
<21 years
Royal Children’s Hospital, Children’s Hospital at Westmead
A Phase I Study of Tagraxofusp With or Without Chemotherapy in paediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
<17 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital
Phase II Study of Ribociclib and Everolimus Following Radiotherapy in paediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT
12 months
|
39 years
John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in paediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations
12 years
|
39 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
A Pilot Study of Lorlatinib for Treatment of Children with Newly Diagnosed High-Grade Glioma with ROS-1 and ALK Fusion
1 year
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG) – SCREENING PROTOCOL
12 months
|
39 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)
<18 years
Queensland Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
A phase 1/2, open-label safety, tolerability, pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations
<25 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients with Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
12 months
|
25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in paediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas
≤ 25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
